Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results

Genitourinary Cancer

Gemcitabine versus Bacillus Calmette-Guerin for Intravesical Therapy in Treatment-Naïve Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

J Urol

Khene ZE, Bhanvadia R, Attia S, Ito W, Trevino I, Woldu SL, Margulis V, Lotan Y

doi: 10.1097/JU.0000000000004472

Genitourinary Cancer

Real-word outcomes for high-risk non-muscle-invasive bladder cancer: screened patients for the BRAVO trial

BJU Int

Conroy S, Jubber I, Noon AP, Rosario DJ, Griffin J, Morgan S, Hubbard R, Kennish S, Mitchell S, Venugopal S, Linton K, Rajasundaram R, Hussain SA, Catto JWF

doi: 10.1111/bju.16516

Genitourinary Cancer

Predicting response to intravesical BCG in high-risk non-muscle invasive bladder cancer using an artificial intelligence-powered pathology assay: development and validation in an international 12 center cohort

J Urol

Lotan Y, Krishna V, Abuzeid WM, Launer B, Chang SS, Krishna V, Shingi S, Gordetsky JB, Gerald T, Woldu S, Shkolyar E, Hayne D, Redfern A, Spalding L, Stewart C, Eyzaguirre E, Imtiaz S, Narayan VM, Packiam VT, O'Donnell MA, Li R, Baekelandt L, Joniau S, Zuiverloon T, Fernandez MI, Schultz M, Hensley PJ, Allison D, Taylor JA, Hamza A, Kamat A, Nimgaonkar V, Sonawane S, Miller DL, Watson D, Vrabac D, Joshi A, Shah JB, Williams SB

doi: 10.1097/JU.0000000000004278

Genitourinary Cancer

A Systematic Review of Novel Intravesical Approaches for the Treatment of Patients with Non-muscle-invasive Bladder Cancer

Eur Urol

Ghodoussipour S, Bivalacqua T, Bryan RT, Li R, Mir MC, Palou J, Psutka SP, Sundi D, Tyson MD, Inman BA

doi: 10.1016/j.eururo.2025.02.010

Multiple Myeloma (MM)

Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database

Blood Cancer J

Rajkumar SV, Mateos MV, Schaeffer M, Lin X, Bathija S, Gupta-Werner N, Lam A, Carson R, Dennis R, Kaila S, Matt K, Duran J, Lonial S

doi: 10.1038/s41408-024-01170-z

Genitourinary Cancer

Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274

J Clin Oncol

Galsky MD, Witjes JA, Gschwend JE, Milowsky MI, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat SF, Park SH, Agerbaek M, Jha G, Stenner F, Ye D, Giudici F, Dutta S, Askelson M, Nasroulah F, Zhang J, Brophy L, Bajorin DF

doi: 10.1200/JCO.24.00340

Genitourinary Cancer

A Polygenic Risk Score for Late Bladder Toxicity Following Radiotherapy for Non-Metastatic Prostate Cancer

Cancer Epidemiol Biomarkers Prev

Farazi M, Yang X, Gehl CJ, Barnett GC, Burnet NG, Chang-Claude J, Parker CC, Dunning AM, Azria D, Choudhury A, Rancati T, De Ruysscher D, Seibold P, Sperk E, Talbot CJ, Veldeman L, Webb AJ, Elliott R, Aguado-Barrera ME, Carballo AM, Fuentes-Ríos O, Gómez-Caamaño A, Peleteiro P, Vega A, Ostrer H, Rosenstein BS, Saito S, Parliament M, Usmani N, Marples B, Chen Y, Morrow G, Messing E, Janelsins MC, Hall W, West CML, Auer PL, Kerns S

doi: 10.1158/1055-9965.EPI-24-1228

Genitourinary Cancer

Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study

Eur Urol

Karpinski MJ, Rahbar K, Bögemann M, Nikoukar LR, Schäfers M, Hoberück S, Miederer M, Hölscher T, Rasul S, Miszczyk M, Lanfranchi F, Bauckneht M, Pfob CH, Kind F, Goffin K, Hüsing A, Kesch C, Herrmann K, Stuschke M, Gafita A, Hüsing J, Calais J, Hofman MS, Hope TA, Miksch J, Soeterik TFW, Di Giorgio A, Farolfi A, Bjartell A, Trägårdh E, Unterrainer LM, Holzgreve A, Sheikh GT, Rauscher I, Eiber M, Hadaschik BA, Fendler WP

doi: 10.1016/j.eururo.2025.04.017

Genitourinary Cancer

The impact of treatment for muscle-invasive bladder cancer on health-related quality of life

BJU Int

Nuijens ST, van Hoogstraten LMC, Terpstra NB, Beeren I, Vrieling A, Wijnen EM, Meijer RP, Kiemeney LA, Witjes JA, Aben KKH

doi: 10.1111/bju.16736

Related content

Gemcitabine versus Bacillus Calmette-Guerin for Intravesical Therapy in Treatment-Naïve Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Real-word outcomes for high-risk non-muscle-invasive bladder cancer: screened patients for the BRAVO trial

Predicting response to intravesical BCG in high-risk non-muscle invasive bladder cancer using an artificial intelligence-powered pathology assay: development and validation in an international 12 center cohort

A Systematic Review of Novel Intravesical Approaches for the Treatment of Patients with Non-muscle-invasive Bladder Cancer

Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database

Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274

A Polygenic Risk Score for Late Bladder Toxicity Following Radiotherapy for Non-Metastatic Prostate Cancer

Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study

The impact of treatment for muscle-invasive bladder cancer on health-related quality of life